Review





Similar Products

neonatal cardiac myocyte isolation system  (Worthington Biochemical)
94
Worthington Biochemical neonatal cardiac myocyte isolation system
Neonatal Cardiac Myocyte Isolation System, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pmc13096963-53-20-25?v=Worthington+Biochemical
Average 94 stars, based on 1 article reviews
neonatal cardiac myocyte isolation system - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
human cardiac myocytes  (PromoCell)
95
PromoCell human cardiac myocytes
Human Cardiac Myocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pmc13194094-38-0-5?v=PromoCell
Average 95 stars, based on 1 article reviews
human cardiac myocytes - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
human cardiomyocytes  (PromoCell)
95
PromoCell human cardiomyocytes
a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human <t>cardiomyocytes.</t>
Human Cardiomyocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pmc13087250-406-0-8?v=PromoCell
Average 95 stars, based on 1 article reviews
human cardiomyocytes - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
heart  (PromoCell)
95
PromoCell heart
a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human <t>cardiomyocytes.</t>
Heart, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pm41986718-573-10-11?v=PromoCell
Average 95 stars, based on 1 article reviews
heart - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
ventricles  (PromoCell)
95
PromoCell ventricles
a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human <t>cardiomyocytes.</t>
Ventricles, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pm41986718-573-6-11?v=PromoCell
Average 95 stars, based on 1 article reviews
ventricles - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
human ventricular cardiomyocytes  (PromoCell)
95
PromoCell human ventricular cardiomyocytes
a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human <t>cardiomyocytes.</t>
Human Ventricular Cardiomyocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pm41934819-480-10-15?v=PromoCell
Average 95 stars, based on 1 article reviews
human ventricular cardiomyocytes - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
neonatal rat cardiac myocytes  (Dawley Inc)
86
Dawley Inc neonatal rat cardiac myocytes
a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human <t>cardiomyocytes.</t>
Neonatal Rat Cardiac Myocytes, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cardiac+myocytes/pmc13059456-43-0-13?v=Dawley+Inc
Average 86 stars, based on 1 article reviews
neonatal rat cardiac myocytes - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human cardiomyocytes.

Journal: npj Imaging

Article Title: [3- 11 C]Pyruvate PET detects alterations in cardiac pyruvate metabolism induced by doxorubicin chemotherapy

doi: 10.1038/s44303-026-00165-8

Figure Lengend Snippet: a [3- 14 C]Pyruvate flux in HCMs was evaluated in a time-dependent manner (0, 2, 4, 6, and 8 min). Cells were treated with vehicle (control; CTRL) or 0.1 µM DOX for 2 × 48 h ( n = 6 per condition). b Western blot analysis of MPC1, MPC2, and MCT1 expression from HCM treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h). Vinculin was used as a reference. c [3- 14 C]Pyruvate uptake was assessed in HCMs treated with vehicle (CTRL), UK5099 (100 µM for 72 h), or DOX (0.1 µM for 2 × 48 h) for 8 min. d [3- 14 C]Pyruvate uptake in HCM treated with scramble siRNA (100 nM for 24 h) or MPC1/2 siRNA (50 nM of each MPC siRNA—total concentration of 100 nM—for 24 h) for 8 min. e Hypothesized effect of DOX treatment on the cellular fate of [3- 14 C]pyruvate, which can be retained within the cell as [3- 14 C]pyruvate or another labeled metabolite, released into the media as [3- 14 C]lactate, [3- 14 C]pyruvate, or another species, or released to the air as [ 14 C]CO 2 . The illustration was created with BioRender. f [ 14 C]CO₂ capture assay was performed following an 8-min incubation of HCM with [3- 14 C]pyruvate. Data are presented as the mean ± s.d. * p < 0.05; *** p < 0.001; **** p < 0.0001. Statistical analysis was performed using Pearson correlation coefficients ( a R 2 = 0.9728), two-way ANOVA ( c ), unpaired t-test ( d ), or one-way ANOVA ( f ). HCM human cardiomyocytes.

Article Snippet: Human cardiomyocytes (HCMs) isolated from adult left ventricles (PromoCell, Heidelberg, Germany) were cultured according to the manufacturer’s instructions.

Techniques: Control, Western Blot, Expressing, Concentration Assay, Labeling, Incubation